Overview

IC14 in Adult Patients With Dengue Fever

Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled, safety, PK/PD and preliminary efficacy study of intravenous IC14 in adult patients in a dengue-endemic region presenting with fever > 38°C for < 48 hours with a positive NS1 strip assay or reverse-transcriptase polymerase chain reaction assay for dengue virus.
Phase:
Phase 2
Details
Lead Sponsor:
Implicit Bioscience